Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine discontinuation in Crohn's disease patients in remission on anti-TNF-α therapy
ChiCTR2500110821Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Salcrozine in Crohn's disease (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Clinical remission response rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
Salcrozine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2500110821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110821.